Eucure Biopharma is a wholly-owned subsidiary of Biocytogen committed to clinical development.
Biocytogen is an international biotechnology company that develops new drugs based on innovative technology. Biocytogen is committed to becoming the birthplace of global new drugs with the mission of focusing on technological innovation, continuous new drug production, and safeguarding of human health. Biocytogen has established a unique new drug development system covering the whole drug development process by organically integrating the single-cell antibody discovery technology platform, efficient gene editing model development platform, large-scale animal model supply platform, and rapid animal in vivo and in vitro drug efficacy evaluation platform with powerful clinical development capabilities based on the fully human antibody RenMab®, RenLiteTM, and RenNanoTM mice independently developed by Biocytogen with completely independent intellectual property rights. Therefore, Biocytogen successfully transformed into Biotech, and will focus more on development of innovative antibody drugs in the future. As implementation of the large-scale antibody drug development - "Project Integrum", Biocytogen will work with global partners to jointly accelerate the new drug development. Biocytogen is headquartered in Beijing, with branches in Haimen (Jiangsu), Boston, Shanghai. Eucure Biopharma, a wholly-owned subsidiary of Biocytogen, focuses on clinical development.